Table of Contents

• 23andMe

• U.S. Moody’s Downgrade

Top Stories Today

23andMe

Regeneron Pharmaceuticals has agreed to acquire nearly all of 23andMe’s core operations for $256 million after the genetic testing firm filed for bankruptcy earlier this year. The acquisition includes the company’s consumer DNA analysis service and research units, but excludes its telemedicine arm, Lemonaid Health, which will be shut down. Regeneron plans to retain staff from the acquired divisions and aims to continue 23andMe’s mission of empowering individuals through personal health insights. The deal, pending court approval, has drawn regulatory attention due to ongoing concerns about the security of customer genetic information.

U.S. Moody’s Downgrade

U.S. government bond yields remained elevated Monday after Moody’s cut the nation’s credit rating by one level, citing concerns over rising debt and interest expenses. The 30-year Treasury briefly topped 5%, a level last seen in late 2023, while the 10-year also climbed. Though yields retreated slightly later in the session due to renewed bond buying, the downgrade sparked renewed scrutiny of the country's fiscal health. Moody’s was the final major ratings agency to strip the U.S. of its top rating, pointing to persistent budget deficits, growing borrowing costs, and stalled efforts to implement long-term fiscal reforms.

Thanks for reading, subscribe to The Standard Lens for more.